Bicara Therapeutics Inc. Common Stock (BCAX) 10-Year Financial Performance & Capital Metrics

BCAX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutBicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.Show more

Revenue $0
EBITDA -$82M -106.5%
Net Income -$68M -30.8%
EPS (Diluted) -1.25 -25.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -19.14% +62.9%
ROIC -2129.28%
Debt/Equity 0.00 -50.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 85 (top 15%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-104.31%

EPS CAGR

10Y-

5Y-

3Y-

TTM-104.59%

ROCE

10Y Avg-30.47%

5Y Avg-30.47%

3Y Avg-30.47%

Latest-21.4%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0
Revenue Growth %	-	-	-
Cost of Goods Sold+	0	0	0
COGS % of Revenue	-	-	-
Gross Profit+	0	0	0
Gross Margin %	-	-	-
Gross Profit Growth %	-	-	-
Operating Expenses+	37.66M	39.89M	82.39M
OpEx % of Revenue	-	-	-
Selling, General & Admin	6.34M	9.27M	18.77M
SG&A % of Revenue	-	-	-
Research & Development	31.31M	30.62M	63.62M
R&D % of Revenue	-	-	-
Other Operating Expenses	0	0	0
Operating Income+	-37.66M	-39.89M	-82.39M
Operating Margin %	-	-	-
Operating Income Growth %	-	-0.06%	-1.07%
EBITDA+	-37.65M	-39.87M	-82.33M
EBITDA Margin %	-	-	-
EBITDA Growth %	-	-0.06%	-1.07%
D&A (Non-Cash Add-back)	10K	19K	56K
EBIT	-37.73M	-39.89M	-82.39M
Net Interest Income+	-108K	1.31M	14.58M
Interest Income	4K	1.31M	14.58M
Interest Expense	112K	0	0
Other Income/Expense	-188K	-12.09M	14.58M
Pretax Income+	-37.84M	-51.98M	-67.81M
Pretax Margin %	-	-	-
Income Tax+	1K	5K	187K
Effective Tax Rate %	1%	1%	1%
Net Income+	-37.84M	-51.98M	-68M
Net Margin %	-	-	-
Net Income Growth %	-	-0.37%	-0.31%
Net Income (Continuing)	-37.84M	-51.98M	-68M
Discontinued Operations	0	0	0
Minority Interest	0	0	0
EPS (Diluted)+	-0.73	-1.00	-1.25
EPS Growth %	-	-0.37%	-0.25%
EPS (Basic)	-0.73	-1.00	-1.25
Diluted Shares Outstanding	51.76M	51.76M	54.42M
Basic Shares Outstanding	51.76M	51.76M	54.42M
Dividend Payout Ratio	-	-	-

Balance Sheet

	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.98M	231.07M	502.53M
Cash & Short-Term Investments	4.16M	230.44M	489.71M
Cash Only	4.16M	230.44M	489.71M
Short-Term Investments	0	0	0
Accounts Receivable	0	0	0
Days Sales Outstanding	-	-	-
Inventory	0	0	0
Days Inventory Outstanding	-	-	-
Other Current Assets	68K	100K	12.82M
Total Non-Current Assets+	1.72M	2.91M	66.66M
Property, Plant & Equipment	636K	815K	845K
Fixed Asset Turnover	-	-	-
Goodwill	0	0	0
Intangible Assets	0	0	0
Long-Term Investments	0	0	0
Other Non-Current Assets	1.08M	2.09M	6.62M
Total Assets+	6.7M	233.98M	569.2M
Asset Turnover	-	-	-
Asset Growth %	-	33.91%	1.43%
Total Current Liabilities+	23.9M	15.09M	17.99M
Accounts Payable	5.14M	3.19M	4.51M
Days Payables Outstanding	-	-	-
Short-Term Debt	0	0	607K
Deferred Revenue (Current)	0	0	0
Other Current Liabilities	0	0	9.79M
Current Ratio	0.21x	15.32x	27.93x
Quick Ratio	0.21x	15.32x	27.93x
Cash Conversion Cycle	-	-	-
Total Non-Current Liabilities+	85K	389K	59.33M
Long-Term Debt	0	0	0
Capital Lease Obligations	0	372K	131K
Deferred Tax Liabilities	0	0	59.2M
Other Non-Current Liabilities	85K	17K	0
Total Liabilities	23.98M	15.47M	77.32M
Total Debt+	0	657K	738K
Net Debt	-4.16M	-229.78M	-488.97M
Debt / Equity	-	0.00x	0.00x
Debt / EBITDA	-	-	-
Net Debt / EBITDA	-	-	-
Interest Coverage	-336.21x	-	-
Total Equity+	-17.28M	218.51M	491.88M
Equity Growth %	-	13.65%	1.25%
Book Value per Share	-0.33	4.22	9.04
Total Shareholders' Equity	-17.28M	218.51M	491.88M
Common Stock	2K	2K	7K
Retained Earnings	-101.04M	-153.02M	-221.02M
Treasury Stock	0	0	0
Accumulated OCI	0	0	0
Minority Interest	0	0	0

Cash Flow

	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-32.08M	-45.63M	-74.75M
Operating CF Margin %	-	-	-
Operating CF Growth %	-	-0.42%	-0.64%
Net Income	-37.84M	-51.98M	-68M
Depreciation & Amortization	10K	19K	56K
Stock-Based Compensation	810K	1.9M	7.4M
Deferred Taxes	0	0	0
Other Non-Cash Items	0	14.06M	-77K
Working Capital Changes	4.95M	-9.62M	-14.13M
Change in Receivables	0	0	0
Change in Inventory	0	0	0
Change in Payables	0	0	2.64M
Cash from Investing+	-192K	-586K	-9K
Capital Expenditures	-192K	-586K	-71K
CapEx % of Revenue	-	-	-
Acquisitions	-	-	-
Investments	-	-	-
Other Investing	0	0	62K
Cash from Financing+	31.7M	272.5M	334.03M
Debt Issued (Net)	-	-	-
Equity Issued (Net)	-	-	-
Dividends Paid	0	0	0
Share Repurchases	-	-	-
Other Financing	160K	149K	1.6M
Net Change in Cash	-	-	-
Free Cash Flow+	-32.27M	-46.21M	-74.82M
FCF Margin %	-	-	-
FCF Growth %	-	-0.43%	-0.62%
FCF per Share	-0.62	-0.89	-1.37
FCF Conversion (FCF/Net Income)	0.85x	0.88x	1.10x
Interest Paid	0	0	0
Taxes Paid	1K	0	0

Key Ratios

Metric	2022	2023	2024
Return on Equity (ROE)	-	-51.67%	-19.14%
Return on Invested Capital (ROIC)	-	-	-2129.28%
Debt / Equity	-	0.00x	0.00x
Interest Coverage	-336.21x	-	-
FCF Conversion	0.85x	0.88x	1.10x

Frequently Asked Questions

Growth & Financials

Bicara Therapeutics Inc. Common Stock (BCAX) grew revenue by 0.0% over the past year. Growth has been modest.

Bicara Therapeutics Inc. Common Stock (BCAX) reported a net loss of $121.5M for fiscal year 2024.

Dividend & Returns

Bicara Therapeutics Inc. Common Stock (BCAX) has a return on equity (ROE) of -19.1%. Negative ROE indicates the company is unprofitable.

Bicara Therapeutics Inc. Common Stock (BCAX) had negative free cash flow of $113.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener